AWH - Aspira Women's Health Inc. Stock Price, Fair Value and News

2.65USD+0.01 (+0.38%)Market Closed

Market Summary

USD2.65+0.01

Market Closed

0.38%

AWH Stock Price

View Fullscreen

AWH RSI Chart

AWH Valuation

Market Cap

33.0M

Price/Earnings (Trailing)

-2.24

Price/Sales (Trailing)

3.6

EV/EBITDA

-1.71

Price/Free Cashflow

-4.17

AWH Price/Sales (Trailing)

AWH Profitability

EBT Margin

-208.82%

Return on Equity

1.1K%

Return on Assets

-205.76%

Free Cashflow Yield

-24%

AWH Fundamentals

AWH Revenue

Revenue (TTM)

9.2M

Rev. Growth (Yr)

-1.07%

Rev. Growth (Qtr)

-3.92%

AWH Earnings

Earnings (TTM)

-14.7M

Earnings Growth (Yr)

29.63%

Earnings Growth (Qtr)

-49.85%

Breaking Down AWH Revenue

Last 7 days

-10.8%

Last 30 days

-24.1%

Last 90 days

-45.1%

Trailing 12 Months

-37.6%

How does AWH drawdown profile look like?

AWH Financial Health

Current Ratio

1.16

Debt/Equity

-0.99

Debt/Cashflow

-5.85

AWH Investor Care

Shares Dilution (1Y)

48.37%

Diluted EPS (TTM)

-1.45

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	8.6M	9.0M	9.2M	9.2M
2022	7.2M	7.5M	7.9M	8.2M
2021	4.9M	6.0M	6.4M	6.8M
2020	5.0M	4.6M	4.5M	4.7M
2019	3.2M	3.6M	4.2M	4.5M
2018	1.5M	2.0M	2.5M	3.1M
2017	477.0K	632.0K	787.0K	942.0K
2016	1.7M	1.9M	2.2M	322.0K
2015	3.2M	3.4M	3.4M	2.2M
2014	2.5M	2.5M	2.5M	2.5M
2013	2.1M	2.1M	2.1M	2.6M
2012	1.8M	1.8M	1.8M	2.1M
2011	1.4M	1.5M	1.7M	1.9M
2010	0	0	0	1.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Aspira Women's Health Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 26, 2024	sandford nicole	bought	-	-	2,400	president & ceo
Dec 06, 2023	merchant minh hoang	sold	-3,302	3.37	-980	secretary & general counsel
Dec 06, 2023	sandford nicole	bought	16,800	3.36	5,000	president & ceo
Nov 17, 2023	merchant minh hoang	acquired	-	-	10,000	secretary & general counsel
Nov 17, 2023	hombeck torsten	acquired	-	-	30,000	chief financial officer
Sep 08, 2023	hombeck torsten	bought	9,657	4.3	2,246	chief financial officer
Aug 29, 2023	sandford nicole	acquired	-	-	26,367	president and ceo
Aug 29, 2023	sandford nicole	acquired	-	-	26,467	president & ceo
Aug 28, 2023	jordan veronica gh	acquired	-	-	7,045	-
Aug 28, 2023	fralick celeste rachelle	acquired	-	-	13,252	-

Which funds bought or sold AWH recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	B. Riley Wealth Advisors, Inc.	reduced	-30.1	-59,829	672,005	0.02%
May 15, 2024	Tower Research Capital LLC (TRC)	added	84.87	3,078	10,683	-%
May 15, 2024	Royal Bank of Canada	reduced	-98.48	-38,000	-	-%
May 15, 2024	NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	sold off	-100	-2,011	-	-%
May 15, 2024	Northeast Financial Consultants Inc	unchanged	-	-22,967	72,652	-%
May 15, 2024	ARMISTICE CAPITAL, LLC	new	-	3,586,700	3,586,700	0.05%
May 15, 2024	Squarepoint Ops LLC	added	65.56	16,169	78,858	-%
May 15, 2024	BANK OF AMERICA CORP /DE/	added	0.59	-28,068	90,998	-%
May 15, 2024	MORGAN STANLEY	added	6.51	-1,770	7,508	-%
May 15, 2024	STATE STREET CORP	unchanged	-	-17,884	56,572	-%

Are Funds Buying or Selling AWH?

Are funds buying AWH calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AWH

No. of Funds

Unveiling Aspira Women's Health Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	schultz eric adam	4.41%	543,998	SC 13G/A
Dec 26, 2023	schultz eric adam	263%	543,998	SC 13G
Jul 26, 2023	schuler jack w	18.7%	1,883,656	SC 13D/A
Feb 15, 2023	seamark capital lp	5.1%	-	SC 13G/A
Aug 29, 2022	schuler jack w	20.8%	25,885,120	SC 13D/A
Feb 16, 2022	seamark capital lp	5.0%	-	SC 13G/A
Feb 14, 2022	drysdale robert h	-	0	SC 13G
Jan 13, 2022	sharman tanya schuler	5.3%	5,943,881	SC 13D/A
Dec 30, 2021	schuler tino hans	4.3%	4,829,019	SC 13D/A
Dec 30, 2021	schuler henri george	8.2%	9,207,779	SC 13D/A

Recent SEC filings of Aspira Women's Health Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
May 15, 2024	8-K	Current Report
May 14, 2024	4	Insider Trading
May 14, 2024	4	Insider Trading
May 14, 2024	8-K	Current Report
May 10, 2024	DEFA14A	DEFA14A
May 06, 2024	4	Insider Trading
Apr 26, 2024	424B5	Prospectus Filed
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	8-K	Current Report

Peers (Alternatives to Aspira Women's Health Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	11.04%	17.40%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	14.64%	19.44%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	13.71%	10.52%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	13.66%	10.24%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	17.80%	114.36%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.71%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.66%	11.24%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-20.33%	-38.03%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	54.73%	-14.09%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	11.70%	-18.80%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	87.44%	103.94%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-3.25%	-85.34%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-24.07%	-37.65%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	-62.31%	120.18%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Aspira Women's Health Inc. News

Latest updates

Aspira Women's Health Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-3.9%	2,130	2,217	2,491	2,316	2,153	2,072	2,066	1,893	1,851	1,666	1,799	1,496	1,446	1,239	746	1,220	1,308	1,285	1,142	803	922
Gross Profit	-6.9%	1,217	1,307	1,550	1,191	1,240	1,156	966	961	1,014	749	696	603	231	432	153	420	516	336	234	109	169
Operating Expenses	3.4%	5,607	5,423	5,871	6,960	6,331	9,736	9,186	10,208	9,960	10,440	8,768	6,489	6,305	4,713	3,979	4,220	3,920	4,186	4,539	3,828	2,993
S&GA Expenses	3.4%	1,760	1,702	1,772	2,562	2,888	3,950	3,580	4,497	4,877	5,083	4,018	3,108	2,843	2,152	1,733	2,115	2,076	2,425	2,780	2,364	1,596
R&D Expenses	9.7%	1,095	998	693	1,231	1,002	2,157	1,410	1,348	1,453	1,518	1,471	872	734	595	380	395	244	340	225	209	125
EBITDA Margin	-0.6%	-2.06*	-2.05*	-2.08*	-2.18*	-2.30*	-2.40*	-2.53*	-2.62*	-2.77*	-2.94*	-3.15*	-3.82*	-4.05*	-	-	-	-	-	-	-	-
Interest Expenses	-83.3%	2.00	12.00	8.00	26.00	27.00	18.00	-10.00	-18.00	-13.00	-14.00	3.00	-24.00	-4.00	5.00	1.00	8.00	20.00	34.00	-2.00	7.00	3.00
EBT Margin	-0.3%	-2.09*	-2.08*	-2.12*	-2.22*	-2.34*	-2.43*	-2.56*	-2.65*	-2.81*	-2.98*	-3.20*	-3.88*	-4.11*	-	-	-	-	-	-	-	-
Net Income	34.4%	-3,089	-4,706	-2,317	-6,578	-4,591	-7,783	-8,243	-9,268	-8,961	-9,707	-7,074	-5,920	-6,081	-4,287	-3,831	-3,706	-3,387	-3,820	-4,314	-3,716	-2,820
Net Income Margin	8.0%	-1.82*	-1.98*	-2.35*	-3.16*	-3.65*	-4.35*	-4.84*	-4.86*	-4.65*	-4.49*	-3.91*	-4.08*	-3.85*	-	-	-	-	-	-	-	-
Free Cashflow	-407.1%	-10,200	3,321	3,413	-5,714	-7,150	-7,568	-6,327	-10,255	-7,679	-8,019	-6,585	-5,296	-4,979	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	14.4%	7,164	6,262	8,662	7,720	11,496	17,373	23,942	24,016	30,861	41,079	48,047	55,829	62,297	19,605	21,265	13,091	10,353	13,828	16,533	18,152	8,254
Current Assets	15.9%	6,122	5,280	7,572	6,862	10,528	16,309	22,976	22,956	29,800	40,005	47,188	54,907	61,373	18,603	20,251	12,690	9,986	13,410	16,050	17,565	7,576
Cash Equivalents	41.4%	3,673	2,597	5,100	4,246	7,535	13,306	20,551	20,480	26,855	37,430	44,870	52,993	59,369	16,631	18,836	10,935	8,132	11,703	14,636	16,179	6,174
Inventory	4.0%	236	227	301	272	302	316	280	191	189	174	137	101	71.00	30.00	45.00	66.00	63.00	25.00	29.00	90.00	98.00
Net PPE	-20.6%	131	165	221	261	305	368	417	438	480	464	498	546	533	583	593	360	318	353	399	472	531
Liabilities	-1.2%	8,527	8,627	9,321	8,248	10,669	10,394	12,764	9,894	9,117	10,907	9,543	8,991	9,972	9,886	6,715	5,824	5,051	5,090	4,706	4,786	4,617
Current Liabilities	3.4%	5,293	5,119	5,162	5,374	5,911	5,527	7,297	7,044	6,139	7,840	6,409	5,791	6,148	6,000	4,615	4,199	3,985	3,978	3,537	3,561	3,336
Short Term Borrowings	-37.9%	416	670	77.00	306	535	764	-	260	519	779	-	204	408	611	476	587	194	303	192	191	190
Long Term Debt	-5.8%	1,347	1,430	1,217	1,334	2,204	2,315	2,426	2,536	2,646	2,718	2,768	2,818	2,718	3,477	1,678	1,615	1,050	1,099	1,148	1,196	1,244
LT Debt, Current	50.0%	249	166	378	259	442	403	343	283	223	201	200	199	201	645	-	-	-	193	-	-	-
LT Debt, Non Current	-100.0%	-	1,430	1,217	1,334	2,204	2,315	2,426	2,536	2,646	2,718	2,768	2,818	2,718	3,477	1,678	1,615	1,050	1,099	1,148	1,196	1,244
Shareholder's Equity	42.4%	-1,363	-2,365	-	-	827	6,979	11,178	14,122	21,744	30,172	38,504	46,838	52,325	9,719	14,550	7,267	5,302	8,738	11,827	13,366	3,637
Retained Earnings	-0.9%	-522,932	-518,300	-515,214	-507,282	-504,965	-501,613	-497,022	-489,239	-480,996	-471,728	-462,767	-453,060	-445,986	-440,066	-433,985	-429,698	-425,867	-422,161	-418,774	-414,954	-410,640
Additional Paid-In Capital	-100.0%	-	515,927	514,544	506,745	505,784	508,584	508,192	503,249	502,628	501,893	501,159	499,786	498,199	449,680	448,431	436,864	431,072	430,802	430,504	428,226	414,202
Shares Outstanding	16.0%	12,344	10,645	10,287	8,473	8,330	8,306	8,296	7,483	7,476	7,476	7,394	7,354	7,244	6,975	-	-	-	-	-	-	-
Float	-	-	-	-	17,677	-	-	-	50,184	-	-	-	477,546	-	-	-	290,268	-	-	-	47,232	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	56.5%	-4,431	-10,188	3,321	3,417	-5,706	-7,076	-7,515	-6,304	-10,173	-7,649	-8,001	-6,490	-5,255	-4,756	-3,067	-3,410	-3,501	-2,871	-3,442	-3,544	-3,108
Share Based Compensation	-14.2%	362	422	681	488	133	420	546	610	838	590	1,178	1,282	489	427	411	441	269	300	296	413	184
Cashflow From Investing	-66.7%	-20.00	-12.00	-	-4.00	-8.00	-74.00	-53.00	-23.00	-82.00	-30.00	-18.00	-95.00	-41.00	-223	-144	-100	-23.00	-12.00	-39.00	-34.00	-48.00
Cashflow From Financing	448.3%	5,269	961	4,176	134	-55.00	-94.00	7,639	-48.00	-70.00	-11.00	146	209	48,034	2,774	11,112	6,313	-47.00	-50.00	1,938	13,583	-30.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AWH Income Statement

2024-03-31

Condensed Consolidated Statements Of Operations (unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Revenue	$ 2,153,000	$ 2,316,000
Cost of revenue:
Cost of revenue	939,000	1,130,000
Gross profit	1,214,000	1,186,000
Operating expenses:
Research and development	906,000	1,267,000
Sales and marketing	1,889,000	2,595,000
General and administrative	3,129,000	3,604,000
Total operating expenses	5,924,000	7,466,000
Loss from operations	(4,710,000)	(6,280,000)
Other income (expense), net:
Change in fair value of warrant liabilities	251,000	(24,000)
Interest (expense) income, net	(5,000)	26,000
Other expense, net	(165,000)	(300,000)
Total other income (expense), net	81,000	(298,000)
Net loss	$ (4,629,000)	$ (6,578,000)
Net loss per share - basic	$ (0.39)	$ (0.79)
Net loss per share - diluted	$ (0.39)	$ (0.79)
Weighted average common shares used to compute basic net loss per common share	11,846,075	8,313,091
Weighted average common shares used to compute diluted net loss per common share	11,846,075	8,313,091
Product [Member]
Revenue:
Revenue	$ 2,153,000	$ 2,315,000
Cost of revenue:
Cost of revenue	$ 939,000	1,130,000
Genetics [Member]
Revenue:
Revenue		$ 1,000

AWH Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (unaudited) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 3,413,000	$ 2,597,000
Accounts receivable, net of reserves of $2 and $15, as of March 31, 2024 and December 31, 2023, respectively	1,531,000	1,459,000
Prepaid expenses and other current assets	942,000	997,000
Inventories	236,000	227,000
Total current assets	6,122,000	5,280,000
Property and equipment, net	131,000	165,000
Right-of-use assets	620,000	528,000
Restricted cash	260,000	258,000
Other assets	31,000	31,000
Total assets	7,164,000	6,262,000
Current liabilities:
Accounts payable	1,643,000	1,261,000
Accrued liabilities	2,797,000	2,863,000
Current portion of long-term debt	249,000	166,000
Short-term debt	416,000	670,000
Current maturities of lease liabilities	188,000	159,000
Total current liabilities	5,293,000	5,119,000
Non-current liabilities:
Long-term debt	1,347,000	1,430,000
Non-current maturities of lease liabilities	487,000	427,000
Warrant liabilities	1,400,000	1,651,000
Total liabilities	8,527,000	8,627,000
Commitments and contingencies (Note 4)
Stockholders' deficit:
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 12,344,104 and 10,645,049 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	12,000	11,000
Additional paid-in capital	521,557,000	515,927,000
Accumulated deficit	(522,932,000)	(518,303,000)
Total stockholders' deficit	(1,363,000)	(2,365,000)
Total liabilities and stockholders' deficit	$ 7,164,000	$ 6,262,000

About Aspira Women's Health Inc.

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

CEO	Ms. Nicole Sandford CPA
WEBSITE	https://aspirawh.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	85

Aspira Women's Health Inc. Frequently Asked Questions

What is the ticker symbol for Aspira Women's Health Inc.? What does AWH stand for in stocks?

AWH is the stock ticker symbol of Aspira Women's Health Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aspira Women's Health Inc. (AWH)?

As of Fri May 17 2024, market cap of Aspira Women's Health Inc. is 32.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers. The fair value of Aspira Women's Health Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aspira Women's Health Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AWH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aspira Women's Health Inc. a good stock to buy?

The fair value guage provides a quick view whether AWH is over valued or under valued. Whether Aspira Women's Health Inc. is cheap or expensive depends on the assumptions which impact Aspira Women's Health Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AWH.

What is Aspira Women's Health Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AWH's PE ratio (Price to Earnings) is -2.24 and Price to Sales (PS) ratio is 3.6. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AWH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aspira Women's Health Inc.'s stock?

In the past 10 years, Aspira Women's Health Inc. has provided -0.244 (multiply by 100 for percentage) rate of return.